Skip to content

Hero image: A pregnant woman taking her blood pressure at home while a maternal-fetal medicine team reviews results remotely

All insights

Technology & Connected Care

Remote Monitoring in High-Risk Pregnancy: A Safety System, Not a Stream of Numbers

10 min readEvidence synthesis
Read the evidence

The question in focus

An evidence-based framework for remote blood pressure, glucose and symptom monitoring in high-risk pregnancy, including devices, escalation and equity.

Evidence at a glance

HR 0.54

hazard of hospital admission in a 2026 antenatal remote-monitoring trial

A multicentre randomised trial found fewer all-cause admissions with remote blood-pressure monitoring, but the study was unblinded and conducted in three metropolitan Australian hospitals.

Remote Versus Office-Based Blood Pressure Monitoring for Women at High Risk of Preeclampsia

The intervention is a clinical pathway

Remote monitoring combines a device, measurement schedule, data transmission, clinical review, thresholds and an escalation response. A blood-pressure cuff alone is not a service. High-risk pregnancy programmes may monitor hypertension, diabetes, weight, oxygen saturation or symptoms, but each variable needs a specific clinical question and validated response plan.

A 2024 systematic review found that postpartum remote blood-pressure monitoring improved completion of blood-pressure follow-up within ten days, without clear increases in unscheduled presentations, readmissions or outpatient prescriptions [1]. Evidence across pregnancy remains heterogeneous, with different devices, populations and outcomes. Remote care should complement rather than automatically replace indicated examinations, laboratory tests, ultrasound and fetal assessment.

  • Define the condition, measurement and decision the programme supports.
  • Use a validated device and correct cuff size.
  • Tell patients exactly when data are and are not monitored.

Measurement quality begins at home

For blood pressure, training should cover rest, posture, arm support, cuff placement, repeat readings and device troubleshooting. Remote-monitoring evidence and prenatal-care guidance both depend on validated measurements embedded in a defined clinical pathway [1][4]. A single implausible value may be technique or equipment, but a severe value or concerning symptoms should trigger the urgent protocol rather than repeated self-testing for hours. Devices validated in general adults may not perform identically in pregnancy or preeclampsia.

For glucose, users need an agreed schedule, target ranges, medicine plan and route for illness or ketones where relevant. Wearable data can create thousands of points without proving benefit. Before adding a sensor, the team should state how it changes treatment, what false alerts look like and whether insurance, phone access or consumable cost could interrupt monitoring.

  • Verify the device against a clinic measurement at onboarding.
  • Provide pictorial and language-accessible instructions.
  • Build a replacement route for malfunctioning equipment.

Escalation reliability is the core safety metric

A monitoring system should specify thresholds, symptoms that override numbers, who receives alerts, maximum response time, after-hours coverage and what happens when the patient cannot be reached. Severe headache, visual change, chest pain, breathlessness, seizure, heavy bleeding, severe abdominal pain or reduced fetal movement require symptom-based pathways regardless of an app result.

ACOG recommends blood-pressure evaluation no later than seven to ten days postpartum for hypertensive disorders and within 72 hours after severe hypertension; remote methods are one mechanism to meet this need [2]. A dashboard should show unanswered alerts and failed transmissions, not only abnormal values. Silent missing data may signal illness, technical failure, language barriers or unstable housing.

  • Audit alert-to-review and alert-to-clinical-action time.
  • Escalate repeated missing data through a supportive, not punitive, workflow.
  • Give every patient a non-digital urgent-care route.

Early trial results need careful translation

A 2026 multicentre Australian randomised trial in people at high risk of preeclampsia found remote blood-pressure monitoring was non-inferior for its primary clinical framework and associated with fewer all-cause admissions, hazard ratio 0.54, and fewer hypertension-specific admissions, hazard ratio 0.41 [3]. The trial was unblinded, used smartphone transmission and took place in three metropolitan hospitals, so implementation elsewhere requires local evaluation.

Reduction in visits or admissions is valuable only if maternal and fetal outcomes remain safe. Programmes should track severe hypertension, preeclampsia, emergency presentations, preterm birth, growth restriction, patient burden and inequities as well as utilisation. An apparent efficiency gain can simply shift work to pregnant people and families. Time, anxiety, data costs and unpaid caregiving effort belong in the evaluation.

  • Preserve in-person care for people who prefer or need it.
  • Measure clinical outcomes and workload transferred to patients.
  • Validate the pathway in rural, low-connectivity and multilingual populations.

Interoperability should improve continuity, not surveillance

Remote readings should enter the clinical record with device identity, time, units and context. Duplicate manual entry creates errors. WHO guidance on digital health stresses that digital interventions must strengthen health systems rather than substitute for accountable care [5]. At the same time, continuous location, microphone or unrelated phone data are rarely necessary. Data minimisation and explicit consent are especially important in pregnancy and in households affected by intimate partner violence.

The safest programme is deliberately boring: validated equipment, few meaningful alerts, visible accountability and reliable backup. Predictive artificial intelligence may help prioritise data, but it must be prospectively validated, monitored for subgroup performance and unable to close an alert without human accountability. A risk score should never reassure against severe symptoms.

  • Integrate readings with provenance and audit trails.
  • Collect only data needed for a defined clinical purpose.
  • Make algorithmic prioritisation visible to clinicians and patients.

What the evidence cannot yet answer

  • Remote-monitoring studies vary widely in population, device, clinical response and outcome definitions.
  • Evidence is stronger for blood-pressure follow-up than for many other proposed pregnancy sensors.
  • Trials from connected tertiary centres may not generalise to rural, low-connectivity or under-resourced settings.

Questions worth taking into care

  1. Is the device validated in pregnancy and with the correct cuff or sensor configuration?
  2. Who reviews data, during which hours and within what response time?
  3. Which symptoms require urgent care even when the number looks normal?
  4. What happens after missing data, device failure or loss of connectivity?
  5. Does the programme reduce clinical harm without transferring unreasonable burden to patients?

Source record

Evidence used in this review

Sources were selected for clinical authority, methodological relevance and traceability. Links open the original guidance, public-health record or research publication.

  1. [1]
  2. [2]
    Optimizing Postpartum Care

    American College of Obstetricians and Gynecologists · 2018

  3. [3]
  4. [4]
    Tailored Prenatal Care Delivery for Pregnant Individuals

    American College of Obstetricians and Gynecologists · 2025

  5. [5]
Editorial standard

This evidence synthesis is for general information. It does not diagnose a condition or replace care from a qualified health professional. Treatment choices depend on individual history, examination, local guidance and informed preference. Emergency or rapidly worsening symptoms need urgent local medical assessment.